PureTech Health (PRTC) investor relations material

Executive summary

• Achieved major milestones including Seaport's $260M Nasdaq IPO, Celea's $180M financing and Phase III trial initiation, and Gallop's positive Phase 1b data and FDA Fast Track designation.

• Refined strategy focuses on capital efficiency, earlier external funding, and direct value return to shareholders.

• Operational runway secured through at least end of 2028, with $220M in cash and investments as of June 30, 2026.

• Retained future economics from Cobenfy and advanced the innovation engine, emphasizing a hub-and-spoke model.

Financial highlights

• Net income for H1 2026 was $67.2M, reversing a $44.6M loss in H1 2025, driven by gains from Seaport's IPO and fair value adjustments.

• Total revenue rose 92% year-over-year to $3.6M, mainly from increased Cobenfy royalties.

• Operating expenses increased 12% to $55.9M, with R&D up 36% to $33.9M due to deupirfenidone Phase III preparations.

• Cash and short-term investments at $220M, down from $277.1M at year-end 2025, reflecting investments in Celea and portfolio activities.

• Significant one-time gains: $120.4M from Seaport fair value increase and $38.3M from loss of significant influence post-IPO.

Outlook and guidance

• Operational runway expected through at least end of 2028, excluding potential inflows from monetization events.

• Focus on maintaining lean operations, selective capital deployment, and increasing capital returns to shareholders.

• At least three concept-stage innovation programs targeted per year, with updates expected in H1 2027.

• Celea expects Phase III SURPASS-IPF topline results in H2 2029; Seaport and Gallop anticipate key clinical milestones in 2027-2028.